Literature DB >> 19285934

The evolution of the natriuretic peptides - Current applications in human and animal medicine.

Roland R J van Kimmenade1, James L Januzzi.   

Abstract

Although natriuretic peptides have played an important role in the fluid homeostasis of vertebrates for over several million years, their importance has only been noticed in the last few decades. Yet, the family of natriuretic peptides have since their discovery, drawn the attention of a broad spectrum of physicians and researchers involved in the maintenance of fluid homeostasis, including marine biologists, basic scientists, physicians and veterinarians. While all natriuretic peptides share a common phylogenetic background, due to differences in receptor-binding affinities, they have evolved into different hormones with clear distinct functions. B-type natriuretic peptide (BNP) is the most studied member of the natriuretic peptide family, and together with its cleavage equivalent amino-terminal proB-type natriuretic peptide (NT-proBNP) these peptides have emerged as important cardiovascular serum markers. However, since their introduction, physicians involved in human or animal medicine have faced common but also different challenges in order to optimally interpret the diagnostic and prognostic value of these novel cardiovascular biomarkers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19285934     DOI: 10.1016/j.jvc.2009.01.001

Source DB:  PubMed          Journal:  J Vet Cardiol        ISSN: 1760-2734            Impact factor:   1.701


  7 in total

1.  Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions.

Authors:  Candace Y W Lee; Brenda K Huntley; Daniel J McCormick; Tomoko Ichiki; S Jeson Sangaralingham; Ondrej Lisy; John C Burnett
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2015-12-10

2.  Investigation of an N-Terminal Prohormone of Brain Natriuretic Peptide Point-of-Care ELISA in Clinically Normal Cats and Cats With Cardiac Disease.

Authors:  A N Harris; S S Beatty; A H Estrada; B Winter; M Bohannon; I Sosa; J Hanscom; C A Mainville; A E Gallagher
Journal:  J Vet Intern Med       Date:  2017-06-15       Impact factor: 3.333

3.  Innovative Therapeutics: Designer Natriuretic Peptides.

Authors:  Laura M G Meems; John C Burnett
Journal:  JACC Basic Transl Sci       Date:  2016-12

4.  Assessment of a bedside test for N-terminal pro B-type natriuretic peptide (NT-proBNP) to differentiate cardiac from non-cardiac causes of pleural effusion in cats.

Authors:  Gabriel Wurtinger; Estelle Henrich; Nicolai Hildebrandt; Nicola Wiedemann; Matthias Schneider; Esther Hassdenteufel
Journal:  BMC Vet Res       Date:  2017-12-20       Impact factor: 2.741

5.  Diagnosis and management of pulmonary hypertension associated with left ventricular diastolic dysfunction.

Authors:  Vinicio A de Jesus Perez; Francois Haddad; Roham T Zamanian
Journal:  Pulm Circ       Date:  2012 Apr-Jun       Impact factor: 3.017

Review 6.  Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.

Authors:  Shihui Fu; Ping Ping; Fengqi Wang; Leiming Luo
Journal:  J Biol Eng       Date:  2018-01-12       Impact factor: 4.355

7.  A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease.

Authors:  Daniel K Newhard; SeungWoo Jung; Randolph L Winter; Sue H Duran
Journal:  J Vet Intern Med       Date:  2018-08-07       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.